Literature DB >> 16462304

Severe gynecomastia in an African boy with perinatally acquired human immunodeficiency virus infection receiving highly active antiretroviral therapy.

Agnieszka Dzwonek1, Margaret Clapson, Simon Withey, Alan Bates, Vas Novelli.   

Abstract

Highly active antiretroviral therapy (HAART) slows the progression of human immunodeficiency virus (HIV) disease and lowers mortality and morbidity in children. Coincident with these advances, an increasing number of side effects are being reported. We describe an adolescent boy with perinatally acquired HIV infection who developed significant bilateral breast enlargement as a result of HAART. He required bilateral mastectomies. Pediatricians need to be aware of less common side effects of HAART.

Entities:  

Mesh:

Year:  2006        PMID: 16462304     DOI: 10.1097/01.inf.0000200138.37519.5b

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  4 in total

1.  Who Gets Severe Gynecomastia Among HIV-infected Children in the United Kingdom and Ireland?

Authors:  Julia Kenny; Katja Doerholt; Di M Gibb; Ali Judd
Journal:  Pediatr Infect Dis J       Date:  2017-03       Impact factor: 2.129

2.  Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa.

Authors:  Christine Njuguna; Annoesjka Swart; Marc Blockman; Gary Maartens; Briony Chisholm; Annemie Stewart; Anri Uys; Karen Cohen
Journal:  AIDS Res Ther       Date:  2016-11-16       Impact factor: 2.250

3.  Breast abnormalities in adolescents receiving antiretroviral therapy.

Authors:  Jackie L Dunlop; Wiedaad Slemming; Kathryn Schnippel; Caroline Makura; Leon J Levin; Sarah Rayne; Marnie Vujovic; Cynthia Firnhaber
Journal:  South Afr J HIV Med       Date:  2019-11-06       Impact factor: 2.744

4.  Efavirenz-induced gynecomastia in a prepubertal girl with human immunodeficiency virus infection: a case report.

Authors:  Mette S van Ramshorst; Magdeline Kekana; Helen E Struthers; James A McIntyre; Remco P H Peters
Journal:  BMC Pediatr       Date:  2013-08-13       Impact factor: 2.125

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.